Leadership: Angela M. Cacace, Ph.D. Vice President of Neuroscience and Platform Biology
Dr. Cacace is the Vice President of Neuroscience and Platform Biology at Arvinas. Angela brings more than two decades of biopharmaceutical research and pharmacology experience, contributing to four marketed drugs and over 18 development candidates. Angela came to the company after serving as the Vice President of Biology at Fulcrum Therapeutics, where, together with her team, she built the biology platform and delivered the first development candidate for the treatment of FSHD. Previously, Angela was the Director of Neuroscience and Genetically Defined Diseases at Bristol-Myers Squibb where she spearheaded alternative therapeutic modalities and was a co-inventor on several development candidates.
Throughout her 19 years at Bristol-Myers Squibb, she has held multiple leadership positions, where she was responsible for building research-wide teams and initiatives including the Lead Profiling Function, GPCR High Throughput Screening Team and the Cellular Resource Team. While serving as a Sr. Principal Scientist in Cancer Biology at Pfizer, together with her team, she discovered a novel anti-angiogenic antibody development candidate.
Angela received her B.S. in biology from Fairfield University, Ph.D. in pharmacology from Columbia University and completed her postdoctoral research in Oncology at Bristol-Myers Squibb and the National Cancer Institute.